CELLECTIS S.A.

In News

Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027 - TipRanks

TipRanks - Jan 08, 2026

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS) - Seeking Alpha

Seeking Alpha - Dec 18, 2025

AstraZeneca, Cellectis targeted in patent lawsuit over gene-editing technology - Reuters

Reuters - Sep 26, 2025

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire - Nov 07, 2025

Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result - Yahoo Finance

Yahoo Finance - Aug 04, 2025

AstraZeneca, Cellectis Sued Over $2.2 Billion Cancer-Drug Deal - Bloomberg Law News

Bloomberg Law News - Sep 26, 2025

Cellectis (CLLS) Receives New 'Buy' Rating from Clear Street | C - GuruFocus

GuruFocus - Dec 23, 2025

Wells Fargo Keeps Their Hold Rating on Cellectis SA (CLLS) - The Globe and Mail

The Globe and Mail - Nov 14, 2025

Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents - PR Newswire

PR Newswire - Sep 26, 2025

Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com

Investing.com - Oct 08, 2025

Cellectis SA updates patent license agreement with University of Minnesota - MSN

MSN - Dec 05, 2025

Can Cellectis S.A. Depositary Receipt stock continue upward trend - Quarterly Portfolio Summary & Step-by-Step Swing Trade Plans - ulpravda.ru

ulpravda.ru - Jan 08, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment